576
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      New driver mutations in non-small-cell lung cancer.

      The Lancet Oncology
      Adaptor Proteins, Signal Transducing, genetics, Carcinoma, Non-Small-Cell Lung, physiopathology, Humans, Lung Neoplasms, Mutation, Oncogene Protein v-akt, Protein-Tyrosine Kinases, Proto-Oncogene Proteins B-raf, Receptor Protein-Tyrosine Kinases, Receptor, ErbB-2

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Treatment decisions for patients with lung cancer have historically been based on tumour histology. Some understanding of the molecular composition of tumours has led to the development of targeted agents, for which initial findings are promising. Clearer understanding of mutations in relevant genes and their effects on cancer cell proliferation and survival, is, therefore, of substantial interest. We review current knowledge about molecular subsets in non-small-cell lung cancer that have been identified as potentially having clinical relevance to targeted therapies. Since mutations in EGFR and KRAS have been extensively reviewed elsewhere, here, we discuss subsets defined by so-called driver mutations in ALK, HER2 (also known as ERBB2), BRAF, PIK3CA, AKT1, MAP2K1, and MET. The adoption of treatment tailored according to the genetic make-up of individual tumours would involve a paradigm shift, but might lead to substantial therapeutic improvements. Copyright © 2011 Elsevier Ltd. All rights reserved.

          Related collections

          Author and article information

          Comments

          Comment on this article